ERAS
Price
$1.67
Change
-$0.04 (-2.34%)
Updated
Sep 17 closing price
Capitalization
485.08M
48 days until earnings call
KYMR
Price
$48.12
Change
-$0.66 (-1.35%)
Updated
Sep 17 closing price
Capitalization
3.49B
42 days until earnings call
Interact to see
Advertisement

ERAS vs KYMR

Header iconERAS vs KYMR Comparison
Open Charts ERAS vs KYMRBanner chart's image
Erasca
Price$1.67
Change-$0.04 (-2.34%)
Volume$1.04M
Capitalization485.08M
Kymera Therapeutics
Price$48.12
Change-$0.66 (-1.35%)
Volume$1.39M
Capitalization3.49B
ERAS vs KYMR Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. KYMR commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and KYMR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (ERAS: $1.66 vs. KYMR: $48.12)
Brand notoriety: ERAS and KYMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 123% vs. KYMR: 210%
Market capitalization -- ERAS: $485.08M vs. KYMR: $3.49B
ERAS [@Biotechnology] is valued at $485.08M. KYMR’s [@Biotechnology] market capitalization is $3.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileKYMR’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • KYMR’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than KYMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while KYMR’s TA Score has 6 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 4 bearish.
  • KYMR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, KYMR is a better buy in the short-term than ERAS.

Price Growth

ERAS (@Biotechnology) experienced а +7.16% price change this week, while KYMR (@Biotechnology) price change was +10.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +6.08%, and the average quarterly price growth was +34.58%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

KYMR is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KYMR($3.49B) has a higher market cap than ERAS($485M). KYMR YTD gains are higher at: 19.612 vs. ERAS (-33.825). ERAS has higher annual earnings (EBITDA): -135.93M vs. KYMR (-267.03M). KYMR has more cash in the bank: 665M vs. ERAS (301M). ERAS has less debt than KYMR: ERAS (49.4M) vs KYMR (85.7M). KYMR has higher revenues than ERAS: KYMR (44.7M) vs ERAS (0).
ERASKYMRERAS / KYMR
Capitalization485M3.49B14%
EBITDA-135.93M-267.03M51%
Gain YTD-33.82519.612-172%
P/E RatioN/AN/A-
Revenue044.7M-
Total Cash301M665M45%
Total Debt49.4M85.7M58%
TECHNICAL ANALYSIS
Technical Analysis
ERASKYMR
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 21 days ago
88%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VTCLX340.52N/A
N/A
Vanguard Tax-Managed Capital App Adm
HFDRX18.88N/A
N/A
Hartford Schroders US MidCap Opps R3
TAGHX35.14N/A
N/A
Transamerica US Growth R6
GTCCX28.71N/A
N/A
Gabelli Global Content & Connect C
CRIHX12.54N/A
N/A
CRM Long/Short Opportunities Instl

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-2.87%
XNCR - ERAS
54%
Loosely correlated
+7.31%
OCUL - ERAS
52%
Loosely correlated
-2.17%
RVMD - ERAS
51%
Loosely correlated
-2.01%
IRON - ERAS
49%
Loosely correlated
+1.15%
CRNX - ERAS
48%
Loosely correlated
+0.29%
More

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been closely correlated with NRIX. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if KYMR jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
-1.35%
NRIX - KYMR
67%
Closely correlated
+1.54%
VERA - KYMR
59%
Loosely correlated
-0.85%
CGON - KYMR
54%
Loosely correlated
+5.48%
RGNX - KYMR
52%
Loosely correlated
-2.59%
LYRA - KYMR
52%
Loosely correlated
+1.25%
More